Alopexx, Inc. (ALPX)

Alopexx will go public soon, but the exact IPO date is still unknown.
IPO Price
Shares Offered
Deal Size
Chart not available yet
Data will show when the stock starts trading.
Market Cap 40.37M
Revenue (ttm) n/a
Net Income (ttm) -956,954
Shares Out 8.07M
EPS (ttm) -0.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About ALPX

Alopexx is a clinical stage biotechnology company developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal, and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG). To date over 75 separate pathogens have been found to express PNAG. While the ultimate decision on the safety and efficacy of our therapeutics will be determined by the FDA and other health authorities, it is our management’s assessment that the broad-spectrum potential of our therapeutics will allow t... [Read more]

Industry Health Care
Sector Biotechnology
Founded 2006
Country United States
Stock Exchange NASDAQ
Ticker Symbol ALPX
Full Company Profile

Financial Performance

Financial Statements


Alopexx IPO Registration Document (S-1)

Alopexx has filed to go public with an IPO on the NASDAQ.

2 years ago - SEC

Biopharma financings cut by a third, transactions track with 2019 and earlier

Financings in the first two months of 2022 amount to only a third of the money raised during the same timeframe of 2021 and the number of transactions is down by 56 percent.

2 years ago - BioWorld

Infectious disease biotech Alopexx files for a $17 million IPO

Alopexx, a Phase 2 biotech developing immune therapies for bacterial, fungal, and parasitic infections, filed on Monday with the SEC to raise up to $17 million in an initial public offering.

2 years ago - Renaissance Capital